Even though melanoma is considered as one of the most immunogenic solid tumors, controlling its development and progression remains a challenge. 1 The cellular and molecular factors underlying the ability of melanoma cells to escape immunosurveillance have not yet been fully characterized. However, this knowledge is essential to develop novel therapeutic approaches that improve the poor outcome associated with metastatic disease. Plasmacytoid dendritic cells (pDCs) have recently emerged as a pivotal but somewhat enigmatic cancer-associated cell type. 2 These cells infiltrate many solid tumors and have a robust capacity to drive effective antitumor immune responses. 3, 4 However, the tumor microenvironment often induce functional alterations in the immune infiltrate leading to tolerance and disease progression. 2, [5] [6] [7] The role of melanoma-infiltrating pDCs in tumor progression and response to therapy remains little explored. pDCs are recruited to primary neoplastic lesions and to sentinel lymph nodes, 8 but this is associated with poor prognosis. 9 Nonetheless, pDCs have been shown not only to exert a direct cytotoxic activity against tumor cells, but also-once activated via Toll-like receptor 7 (TLR7) or TLR9, to effectively control melanoma growth through the priming of efficient antitumor immune responses. 2, 4 This controversy prompted us to investigate the pathophysiological role of pDCs in melanoma. 10 Our study combined the analysis of a large cohort of Stage I-IV melanoma patients (61 blood samples, 54 tumor samples including primary tumors and cutaneous as well as lymph node metastases) with the use of an innovative melanoma-bearing humanized mouse model (OncoHumice). In this model, human CD34 + hematopoietic progenitor cells (HPCs) were transplanted to reconstitute a human immune system in immunodeficient mice, which then were grafted with human melanoma cells.
In melanoma patients, the robust infiltration of cutaneous lesions and lymph node metastases by pDCs has been associated with early relapse, suggesting that these cells play a role in disease progression. In melanoma-bearing humanized mice, human pDCs rapidly and massively migrated to neoplastic lesions and to tumor-draining lymph nodes. pDCs accumulated to larger degree than their myeloid counterparts, underlining a predominant role of this DC subset in melanoma. To understand the link between tumor-infiltrating pDCs and early relapse, we first examined the migratory profile and activation status of these cells. CD62L-expressing pDCs were found in greater proportions in the blood of melanoma patients than in that of healthy subjects, suggesting that pDCs are mobilized by melanoma. Interestingly, pDCs expressed high levels of co-stimulatory molecules at cutaneous tumor sites, but were poorly activated in tumor-draining lymph nodes. Thus, the functional status of pDCs appears to be modulated by their passage through neoplastic lesions. We further evaluated the fitness of tumor-associated pDCs by analyzing their ability to respond to TLR ligands, which normally are potent pDC activators. The pDCs isolated from the neoplastic lesions and blood of melanoma To further investigate the mechanisms through which tumor-polarized pDCs promote such a dramatic functional alteration in adaptive immunity, we analyzed a panel of molecules that are known to polarize immune responses toward a T H 2 or regulatory profile. We observed a significantly increased proportion of pDCs expressing tumor necrosis factor (ligand) superfamily, member 4 (TNFSF4, best known as OX40L) and inducible T-cell co-stimulator ligand (ICOSL) within the tumor microenvironment, correlating with the frequency of IL-13-producing CD4 + and CD8 + T cells or IL-10-secreting CD4 + T cells, respectively. Strikingly, blocking OX40L in pDC/T cell co-cultures dramatically reduced IL-5, IL-13 and TNFα production, whereas ICOSL neutralization specifically inhibited the secretion of IL-10. Thus, melanoma cells instruct pDCs to establish a pro-inflammatory T H 2 and regulatory immunological profile via OX40L and ICOSL. We next investigated which tumor-derived factors would trigger such a functional subversion of pDCs. In both humanized mice and humans, chemokine (C-C motif) ligand 17 (CCL17, also known as TARC), CCL22 (also known as MDC) and matrix metalloproteinase 2 (MMP2) were detected within the tumor microenvironment. CCL17 and CCL22 have previously been involved in the recruitment of T H 2 cells and Tregs, as well as in skewing antitumor immune responses toward a pro-inflammatory T H 2 profile by modulating myeloid DCs. 7 Strikingly, these chemokines promoted the upregulation of OX40L and ICOSL on the surface of pDCs, and high levels of CCL17, CCL22, and MMP2 within neoplastic lesions correlated with early disease relapse in patients.
Melanoma hijacks plasmacytoid dendritic cells to promote its own progression
Altogether, our findings provide novel insights into the mechanisms by which melanoma cells hijack the immune system. This appears to involve a novel pDC-dependent pathway that eventually favor disease progression and early relapse (Fig. 1) . We have previously shown that circulating pDCs expressing chemokine (C-C motif) receptor 6 (CCR6) are recruited to melanomas by CCL20. 8 Tumor-infiltrating pDCs are then prompted to express OX40L and ICOSL which, under MMP2 conditioning, can drive the differentiation of IL-5-and IL.13-producing T H 2 CD4 + and CD8 + T cells, as well as the accumulation of IL-10-producing Tregs. These cells can migrate to neoplastic lesions in response to CCL17 and CCL22, ultimately promoting tumor progression and disease relapse. These advances in the understanding of the complex interactions between malignant cells and the immune system may pave the way to the development of novel therapeutic approaches against melanoma. In this setting, TLR agonists represent a promising means to achieve tumor control by reversing the functional impairment of pDCs. Targeting the tumor microenvironment to disrupt the mechanisms that underlie these immunological defects may improve the prognosis of melanoma patients, as illustrated by the recent clinical success of agents that block immune checkpoints programmed cell death 1 (PDCD1)-and cytotoxic T lymphocyte-associated protein 4 (CTLA4)-targeting antibodies. 
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